EA200600349A1 - Биологически неразлагаемые пептиды; ингибитор ангиотензин превращающего фермента, лекарственное средство и функциональный пищевой продукт - Google Patents

Биологически неразлагаемые пептиды; ингибитор ангиотензин превращающего фермента, лекарственное средство и функциональный пищевой продукт

Info

Publication number
EA200600349A1
EA200600349A1 EA200600349A EA200600349A EA200600349A1 EA 200600349 A1 EA200600349 A1 EA 200600349A1 EA 200600349 A EA200600349 A EA 200600349A EA 200600349 A EA200600349 A EA 200600349A EA 200600349 A1 EA200600349 A1 EA 200600349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
pro
anthiotenzin
independable
conversing
Prior art date
Application number
EA200600349A
Other languages
English (en)
Other versions
EA010098B1 (ru
Inventor
Наоюки Ямамото
Сейити Мизуно
Синго Нисимура
Таканобу Готоу
Кейити Мацуура
Original Assignee
Калпис Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Калпис Ко., Лтд. filed Critical Калпис Ко., Лтд.
Publication of EA200600349A1 publication Critical patent/EA200600349A1/ru
Publication of EA010098B1 publication Critical patent/EA010098B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Настоящее изобретение относится к новым неперевариваемые in vivo пептидам, которые являются высоко абсорбируемыми и плохо перевариваемыми в живом организме, когда они вводятся перорально или другим путем, и, предположительно, будут эффективно проявлять такие функции, как гипотензивный эффект в живом организме, и ингибиторы АСЕ, приготовленные с этими пептидами, и лекарственное средство и функциональный пищевой продукт, предположительно эффективно проявляющие гипотензивный эффект в живом организме. Неперевариваемыми in vivo пептидами являются дипептиды или трипептиды, имеющие Pro на карбоксильных концах, выбранные из группы, состоящей из Ile-Pro, Glu-Pro, Arg-Pro, Gln-Pro, Met-Pro и Ser-Pro-Pro.
EA200600349A 2003-08-01 2004-07-30 Неперевариваемые in vivo пептиды, имеющие активность ингибитора ангиотензинпревращающего фермента, лекарственное средство и пищевой продукт EA010098B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003285007 2003-08-01
PCT/JP2004/010929 WO2005012334A1 (ja) 2003-08-01 2004-07-30 生体内非分解性ペプチド、アンジオテンシン変換酵素阻害剤、医薬及び機能性食品

Publications (2)

Publication Number Publication Date
EA200600349A1 true EA200600349A1 (ru) 2006-08-25
EA010098B1 EA010098B1 (ru) 2008-06-30

Family

ID=34113859

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200600352A EA011570B1 (ru) 2003-08-01 2004-07-30 Гидролизат казеина, способ его получения и применение
EA200600349A EA010098B1 (ru) 2003-08-01 2004-07-30 Неперевариваемые in vivo пептиды, имеющие активность ингибитора ангиотензинпревращающего фермента, лекарственное средство и пищевой продукт

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200600352A EA011570B1 (ru) 2003-08-01 2004-07-30 Гидролизат казеина, способ его получения и применение

Country Status (23)

Country Link
US (3) US20070299014A1 (ru)
EP (2) EP1661909B1 (ru)
JP (3) JP5341300B2 (ru)
KR (3) KR101115557B1 (ru)
CN (3) CN100439393C (ru)
AT (2) ATE411035T1 (ru)
AU (2) AU2004261522B2 (ru)
BR (2) BRPI0413242A (ru)
CA (2) CA2532537A1 (ru)
DE (2) DE602004017202D1 (ru)
DK (2) DK1669463T3 (ru)
EA (2) EA011570B1 (ru)
ES (2) ES2313067T3 (ru)
HK (2) HK1094008A1 (ru)
MX (2) MXPA06000878A (ru)
NO (2) NO20060994L (ru)
NZ (2) NZ545341A (ru)
PL (1) PL1669463T3 (ru)
PT (2) PT1669463E (ru)
TW (2) TWI341866B (ru)
UA (2) UA87278C2 (ru)
WO (2) WO2005012334A1 (ru)
ZA (2) ZA200601746B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088597B2 (en) * 2005-02-24 2012-01-03 Dsm Ip Assets B.V. Blood pressure lowering peptides from glycomacropeptide
EP1874128A1 (en) * 2005-04-28 2008-01-09 Hindustan Unilever Limited Peptides having an ace inhibiting effect
DE602006020028D1 (de) * 2005-04-28 2011-03-24 Unilever Nv Gesundheitsfördernde peptide und sie enthaltende zusammensetzungen
ZA200709009B (en) * 2005-04-28 2009-01-28 Unilever Plc Peptides having an ace inhibiting effect
US20100151080A1 (en) 2005-07-26 2010-06-17 Calpis Co., Ltd. Process for production of fermented milk and fermented milk beverage/food
EP2340725A1 (en) 2005-10-28 2011-07-06 Nestec S.A. Methods for the use of branched chain amino acids
EP1992354B1 (en) * 2006-02-09 2014-04-09 Calpis Co., Ltd. Rheumatoid arthritis-preventive agent for oral intake
JP4956164B2 (ja) * 2006-12-06 2012-06-20 味の素株式会社 メラニン輸送及び／又は放出抑制剤
WO2008123095A1 (ja) * 2007-03-27 2008-10-16 Calpis Co., Ltd. 心不全予防剤
CN101095457B (zh) * 2007-06-23 2010-04-07 临夏州华安生物制品有限责任公司 酸水解酪蛋白的生产方法
US20090264363A1 (en) * 2008-03-26 2009-10-22 Ward Loren S Leucine-Rich Peptide Compositions and Methods for Isolation
CN101768209B (zh) * 2009-01-05 2011-08-31 北京林业大学 具有高体内活性的降血压肽及其制备和纯化方法
CN101570568B (zh) * 2009-06-15 2012-05-30 东北农业大学 一种发酵乳中的ace抑制肽及其制备方法
CN102187935B (zh) * 2010-03-19 2012-12-19 江南大学 一种制备酪蛋白磷酸肽与ace抑制肽的方法
CN102399261B (zh) * 2010-09-07 2014-06-25 任发政 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物
US20120115786A1 (en) * 2010-11-09 2012-05-10 Calpis Co., Ltd. Agent for reducing risk in onset of disease ascribable to non-dipper circadian rhythm of blood pressure
JP5718741B2 (ja) * 2011-06-24 2015-05-13 カルピス株式会社 脳機能改善用ペプチドの酵素的製造方法
US9523109B2 (en) 2011-06-24 2016-12-20 Calpis Co., Ltd. Method for enzymatically preparing peptides for use in improvement of brain function
CN107518416A (zh) * 2011-10-14 2017-12-29 雅培制药有限公司 无菌液体蛋白补充剂
CN103215332A (zh) * 2013-04-16 2013-07-24 陕西科技大学 一种分步酶解羊乳酪蛋白制备ace抑制肽的方法
CN105637096A (zh) * 2013-10-04 2016-06-01 英诺威有限公司 动物蛋白质的水解产物、其制造方法及其用途
FR3017536B1 (fr) * 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
ES2544153B1 (es) * 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
JP6251667B2 (ja) 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
CN105693817B (zh) 2014-11-27 2020-06-05 西北大学 一类三肽化合物及其制备方法与应用
JP6005202B2 (ja) * 2015-03-19 2016-10-12 アサヒグループホールディングス株式会社 脳機能改善用ペプチドの酵素的製造方法
JP6625366B2 (ja) * 2015-08-05 2019-12-25 学校法人北里研究所 豚肉の熟成中に生成する生理活性ペプチドを含む血圧降下剤及び食品、並びにペプチドを指標とする豚肉の熟成評価法
CN106119325A (zh) * 2016-06-23 2016-11-16 哈尔滨商业大学 一种具有增加肌肉含量和力量作用的酪蛋白水解物的制备方法
CN107375897A (zh) * 2017-08-15 2017-11-24 普维食品发展（上海）有限公司 一种辅助降血压的组合物及其用途
CN107348511B (zh) * 2017-08-21 2018-04-06 东方红（通化）生物医药股份有限公司 一种具有辅助降血压作用的西洋参/人参提取物的发酵提取方法
CN108003231A (zh) * 2017-11-13 2018-05-08 江苏大学 一种降低小分子肽中游离氨基酸含量的方法
CN108588156A (zh) * 2018-04-24 2018-09-28 浙江大学 一种水牛乳酪蛋白抗氧化活性肽的制备方法
SG11202010069SA (en) * 2018-04-26 2020-11-27 Zeria Pharmaceutical Co Ltd Dipeptide and pharmaceutical composition containing same
CN110467649A (zh) * 2019-09-12 2019-11-19 浙江省农业科学院 一种抑制血管紧张素转换酶活性的多肽qeip及其应用
CN113321719B (zh) * 2021-05-20 2022-03-18 澳优乳业（中国）有限公司 一种寡肽及其制备方法与应用
CN114656521B (zh) * 2022-04-01 2023-08-18 广西大学 抑制新型冠状病毒刺突蛋白与ace2结合的化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023087B2 (ja) * 1982-09-04 1985-06-05 工業技術院長 アンジオテンシン転換酵素阻害剤
FR2608051B1 (fr) * 1986-12-15 1989-04-07 Bellon Labor Sa Roger Procede de fabrication d'un hydrolysat enzymatique de proteines riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique
JPH0630615B2 (ja) * 1988-07-27 1994-04-27 江崎グリコ株式会社 低分子ペプチド組成物及びその製造方法
JPH0262828A (ja) 1988-08-26 1990-03-02 Ajinomoto Co Inc 新規ベプチドおよびこれを含有する降圧剤
JPH03120225A (ja) 1989-10-04 1991-05-22 Ajinomoto Co Inc 新規ペプチドおよびこれを含有する降圧剤
DE69127020T2 (de) * 1990-05-18 1998-01-29 Morinaga Milk Industry Co Ltd Milchproteinhydrolysate und Zusammensetzungen zur Verwendung als Haar- und Hautbehandlungsmittel
JP3010795B2 (ja) * 1991-07-04 2000-02-21 不二製油株式会社 ペプチドの苦味除去方法
JP3378279B2 (ja) 1991-11-07 2003-02-17 株式会社日清製粉グループ本社 ペプチドおよびその製造方法
JPH05252979A (ja) * 1992-02-28 1993-10-05 Nippon Steel Corp 低分子ペプチドの製造方法
JP2782142B2 (ja) 1992-07-23 1998-07-30 カルピス株式会社 アンジオテンシン変換酵素阻害剤及びその製造法
DK46793D0 (da) * 1993-04-26 1993-04-26 Novo Nordisk As Enzym
EP0981630B1 (en) * 1997-05-16 2008-11-19 Novozymes, Inc. Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
JP2873327B2 (ja) * 1998-01-23 1999-03-24 工業技術院長 アンジオテンシン変換酵素阻害剤
JP4633876B2 (ja) * 1999-11-11 2011-02-16 カルピス株式会社 トリペプチドの製造方法
KR100744986B1 (ko) * 1999-11-29 2007-08-02 교와 핫코 푸드 가부시키가이샤 식염미 증강방법, 식염미 증강제, 식염미 조미료 및식염미 증강식품
JP4490547B2 (ja) * 2000-03-30 2010-06-30 株式会社 レオロジー機能食品研究所 新規ペプチド、その製造法及び用途
JP4436961B2 (ja) * 2000-07-25 2010-03-24 森永乳業株式会社 蛋白質加水分解物の製造方法
JP2003024012A (ja) * 2001-07-18 2003-01-28 National Institute Of Advanced Industrial & Technology アンジオテンシンｉ変換酵素阻害剤及び血圧降下性機能食品
WO2003044044A1 (fr) * 2001-11-21 2003-05-30 Morinaga Milk Industry Co., Ltd. Nouveau peptide exerçant un effet inhibiteur d'angiotensine convertase
JP2003210138A (ja) 2002-01-24 2003-07-29 Yoko Takenaka 機能性食品、その製造方法及び医薬
US7900438B2 (en) * 2006-07-28 2011-03-08 General Electric Company Heat transfer system and method for turbine engine using heat pipes

Also Published As

Publication number Publication date
TWI341866B (en) 2011-05-11
CA2546497A1 (en) 2005-02-10
US20070299014A1 (en) 2007-12-27
NZ545340A (en) 2010-04-30
CN100439393C (zh) 2008-12-03
UA89616C2 (ru) 2010-02-25
CN101381401A (zh) 2009-03-11
EP1661909A4 (en) 2006-08-30
KR101115560B1 (ko) 2012-03-13
DE602004023210D1 (de) 2009-10-29
CA2532537A1 (en) 2005-02-10
PT1661909E (pt) 2009-12-17
MXPA06000879A (es) 2006-03-30
JP2011102327A (ja) 2011-05-26
KR20110039379A (ko) 2011-04-15
HK1093991A1 (en) 2007-03-16
JPWO2005012542A1 (ja) 2007-09-27
DK1669463T3 (da) 2009-01-26
EA011570B1 (ru) 2009-04-28
EP1669463A4 (en) 2006-08-23
ATE411035T1 (de) 2008-10-15
NO20060995L (no) 2006-02-28
EP1661909B1 (en) 2009-09-16
DE602004017202D1 (de) 2008-11-27
BRPI0413238A (pt) 2006-10-03
PT1669463E (pt) 2009-01-23
ZA200601739B (en) 2007-05-30
ZA200601746B (en) 2007-05-30
AU2004261522B2 (en) 2010-09-16
WO2005012334A1 (ja) 2005-02-10
WO2005012542A1 (ja) 2005-02-10
AU2004261522A1 (en) 2005-02-10
AU2004261855B2 (en) 2010-09-16
CN100398661C (zh) 2008-07-02
EA010098B1 (ru) 2008-06-30
KR101115557B1 (ko) 2012-03-13
NZ545341A (en) 2009-06-26
DK1661909T3 (da) 2010-01-18
ES2331312T3 (es) 2009-12-29
EP1669463B1 (en) 2008-10-15
BRPI0413242A (pt) 2006-10-03
CN1833031A (zh) 2006-09-13
NO20060994L (no) 2006-02-28
TW200505471A (en) 2005-02-16
JP5341300B2 (ja) 2013-11-13
US20110082281A1 (en) 2011-04-07
WO2005012334A8 (ja) 2005-06-30
US20070122451A1 (en) 2007-05-31
AU2004261855A1 (en) 2005-02-10
EP1661909A1 (en) 2006-05-31
PL1669463T3 (pl) 2009-02-27
KR20060118395A (ko) 2006-11-23
EP1669463A1 (en) 2006-06-14
TWI349676B (en) 2011-10-01
TW200507869A (en) 2005-03-01
MXPA06000878A (es) 2006-03-30
JP4669396B2 (ja) 2011-04-13
KR20060120567A (ko) 2006-11-27
HK1094008A1 (en) 2007-03-16
US8580557B2 (en) 2013-11-12
EA200600352A1 (ru) 2006-08-25
CN1832958A (zh) 2006-09-13
ATE442855T1 (de) 2009-10-15
ES2313067T3 (es) 2009-03-01
KR101174299B1 (ko) 2012-08-16
UA87278C2 (ru) 2009-07-10
JPWO2005012334A1 (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
EA200600349A1 (ru) Биологически неразлагаемые пептиды; ингибитор ангиотензин превращающего фермента, лекарственное средство и функциональный пищевой продукт
EP1568377A1 (en) Cysteine protease inhibitor
Guerrero-Zárate et al. Partial characterization of digestive proteases in tropical gar Atractosteus tropicus juveniles
WO2006131586B1 (es) Péptidos bioactivos identificados en hidrolizados enzimáticos de caseínas lácteas y procedimiento de obtención
ATE242003T1 (de) Enzyme zur behandlung von diabetes mellitus typ i
NO20042188L (no) Hydrolysert marint proteinprodukt og et fôrprodukt omfattende dette, fremgangsmate for fremstilling og anvendelse
Sierra-Lopera et al. Optimization of enzymatic hydrolysis of red tilapia scales (Oreochromis sp.) to obtain bioactive peptides
Han et al. Bioactive properties of enzymatic hydrolysates from abdominal skin gelatin of yellowfin tuna (T hunnus albacares)
Gilmartin et al. Production of cod (Gadus morhua) muscle hydrolysates. Influence of combinations of commercial enzyme preparations on hydrolysate peptide size range
CA2549185A1 (en) Peptide inhibiting angiotensin converting enzyme
JP6864539B2 (ja) コラーゲン、ゼラチンおよびコラーゲン加水分解物に含まれるＧｌｙ−Ｘ−Ｙ配列量の測定方法、およびＸ−Ｙ配列量の測定方法
Matkawala et al. Next-generation nutraceuticals: bioactive peptides from plant proteases
González-Félix et al. Optimum activity and partial characterization of chymotrypsin from the sciaenids Cynoscion othonopterus, Cynoscion parvipinnis, and Cynoscion xanthulus
JP2003284551A (ja) アンジオテンシンｉ変換酵素阻害剤
Harun et al. Optimisation of enzymatic protein hydrolysis of Mud Crab (Scylla sp.) to obtain maximum Angiotensin-Converting enzyme inhibitory (ACEI) activity using response surface methodology
BRPI0308978A8 (pt) fragmentos de peptídeos sintéticos ativos
ATE228362T1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
Gustavo et al. Novel vegetal enzymes used in the obtention of protein hydrolyzates and bioactive peptides derived from various sources of meat and meat by-products
MY141221A (en) Casein hydrolyzate, process for producing the same, and use thereof
Jamhari et al. Comparative study on angiotensin converting enzyme inhibitory activity of hydrolysate of meat protein of Indonesian local livestocks.
JP2019054769A (ja) 白髪抑制用食品
TH62270A (th) ไฮโดรไลเสทของโปรตีนหางนมที่แสดงฤทธิ์ทางชีวภาพได้ที่ได้รับการปรับปรุง
DE60224002D1 (de) Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung
Kim et al. Purification and Characterization of Bioactive Peptide Purified from Skate Skin

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU